Dr. Peter Marks, a prominent figure in the FDA and a key player in President Donald Trump's Operation Warp Speed, has been removed from his position.
Marks, an esteemed American hematologist-oncologist, has served as the director of the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration since 2016. In this role, he was instrumental in overseeing the FDA's vaccine programs, particularly during the rapid development and approval of COVID-19 vaccines under the Trump administration.
According to the Gateway Pundit, Marks tendered his resignation following an ultimatum from a Health and Human Services (HHS) official, who reportedly demanded he either resign voluntarily or face termination.
This move, effective April 5, aligns with HHS Secretary Robert F. Kennedy Jr.'s efforts to overhaul the federal health system by removing what he describes as "entrenched bureaucrats peddling 'misinformation and lies.'" The financial markets reacted swiftly to Marks' departure, with shares of vaccine manufacturers such as Moderna and Novavax experiencing significant declines.
In the aftermath of his resignation, Marks has been vocal in his criticism of Robert Kennedy Jr., raising questions about the motivations behind his public appearances. The former FDA official has already begun defending pharmaceutical companies against Kennedy Jr.'s study on autism, highlighting the ongoing influence of powerful industry players.
This situation underscores the persistent efforts to maintain the flow of vaccines, despite concerns about potential harm to Americans. As Marks continues to make media appearances, his actions are likely to draw further scrutiny and debate.
Login